Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent p...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreau, Philippe, Sonneveld, Pieter, Boccadoro, Mario, Cook, Gordon, Mateos, Ma Victoria, Nahi, Hareth, Goldschmidt, Hartmut, Dimopoulos, Meletios A., Lucio, Paulo, Bladé, Joan, Delforge, Michel, Hajek, Roman, Ludwig, Heinz, Facon, Thierry, Miguel, Jesus F. San, Einsele, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Guideline Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959167/
https://www.ncbi.nlm.nih.gov/pubmed/31439675
http://dx.doi.org/10.3324/haematol.2019.224204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959167/
https://www.ncbi.nlm.nih.gov/pubmed/31439675
http://dx.doi.org/10.3324/haematol.2019.224204

Ejemplares similares